Psycheceutical Bioscience has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilising NeuroDirect™ non-systemic drug delivery technology.
This delivery system is designed to topically distribute neuro-active compounds to the back of the neck for immediate action on a dense population of brain nerve endings. These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
CEO of Psycheceutical, Chad Harman, stated: “PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available. Millions of people suffer each year.
“But there is new hope. This patent application supports Psycheceutical’s ongoing drug development plans for its revolutionary NeuroDirect™ topical delivery system that we believe has the potential to provide new solutions and treatments for PTSD and other mental health conditions.”
PTSD is a common mental health condition affecting hundreds of millions of people worldwide, with symptoms ranging from mild to severe. PTSD is commonly interconnected with other mental health conditions, such as anxiety, depression, and substance abuse disorder. People who suffer from PTSD also have a higher risk of suicide.
Chief Medical Officer of Psycheceutical, Dr Julian Bailes, commented: “Psycheceutical is driven to provide new hope for this debilitating disorder by employing cutting-edge technologies for the patients who need it most.
“We look forward to improving current mental health treatments while progressing the capabilities of the psychedelic pharmaceutical category.”
NeuroDirect™ non-systemic delivery technology is protected by several patents and pending applications, and is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck.
This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea and vomiting.
NeuroDirect™ is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
